Dupixent® (dupilumab) approved in the u.s. as first and only treatment for adolescents with chronic rhinosinusitis with nasal polyps (crswnp)

Following priority review, dupixent is now available to patients as young as 12 years with inadequately controlled crswnp current treatment options leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps dupixent is the leading biologic medicine for all five fda-approved indications in new-to-brand prescriptions tarrytown, n.y. and paris, sept.
REGN Ratings Summary
REGN Quant Ranking